Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01104415
Other study ID # LX1606.1-203-CS
Secondary ID LX1606.203, LX10
Status Completed
Phase Phase 2
First received
Last updated
Start date June 15, 2010
Est. completion date February 12, 2014

Study information

Verified date February 2019
Source Lexicon Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the safety and tolerability of orally administered telotristat etiprate (LX1606) in participants with symptomatic carcinoid syndrome.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date February 12, 2014
Est. primary completion date February 12, 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Males and females, aged 18 and older

- Biopsy-proven metastatic carcinoid tumor of the gastrointestinal (GI) tract with disease extent confirmed by computed tomography (CT), magnetic resonance imaging (MRI), or radionuclide imaging

- Symptomatic carcinoid syndrome (=4 bowel movements per day)

- Ability to provide written informed consent

Exclusion Criteria:

- = 12 high-volume, watery bowel movements per day

- Sponsor-unacceptable clinical laboratory values for hematology and liver function tests at screening

- Karnofsky status =70% - unable to care for self

- Surgery within 60 days prior to screening

- A history of short bowel syndrome

- Life expectancy < 12 months

- History of substance or alcohol abuse within 2 years prior to screening

- Administration of any investigational drug within 30 days of screening or any therapeutic protein or antibody within 90 days of screening

Study Design


Intervention

Drug:
Telotristat etiprate
Telotristat etiprate capsules orally three times daily.

Locations

Country Name City State
Germany Lexicon Investigational Site Bad Berka
Germany Lexicon Investigational Site Berlin
Germany Lexicon Investigational Site Halle
Germany Lexicon Investigational Site Lubeck
Germany Lexicon Investigational Site Marburg
Germany Lexicon Investigational Site Munich
United Kingdom Lexicon Investigational Site Basingstoke
United Kingdom Lexicon Investigational Site Cambridge
United Kingdom Lexicon Investigational Site London
United Kingdom Lexicon Investigational Site Manchester

Sponsors (1)

Lead Sponsor Collaborator
Lexicon Pharmaceuticals

Countries where clinical trial is conducted

Germany,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Drug-Related TEAEs in the Core Phase An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. Treatment-emergent AEs were defined as any AEs reported after the first dose of treatment on Day 1. Baseline up to Week 12 in the Core Phase
Primary Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Drug-Related TEAEs in the Extension Period An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. Treatment-emergent AEs were defined as any AEs reported after the first dose of treatment on Day 1. Up to 124 Weeks in the Extension Period
Secondary Change From Baseline in Number of Bowel Movements (BMs) Participants recorded the number of bowel movements in a daily diary. The change from baseline value was calculated as the difference between mean numbers of BMs of the post-baseline interval (Weeks 9 to 12) and baseline. A negative change from baseline indicates improvement. Baseline for the Extension Period was defined as non-missing assessment in Run-in period prior to the first dose of study drug. Core Phase: Baseline to Weeks 9-12; Extension Period: Baseline to Week 24
Secondary Change From Baseline in Stool Form/Consistency Participants assessed stool form/consistency in a daily diary using a 6-point scale (0-none, 1-hard, 2-firm, 3-soft, 4-loose, 5-watery). The change from the baseline value was calculated as the difference between a mean score of the post-baseline interval (Weeks 9 to 12) and baseline. 0 indicates the best score and 5 indicates the worst score. A negative change from baseline indicates improvement. Baseline for the Extension Period was defined as non-missing assessment in Run-in period prior to the first dose of study drug. Core Phase: Baseline to Weeks 9-12; Extension Period: Baseline to Week 24
Secondary Change From Baseline in Percentage of Days With Sensation of Urgency to Defecate Participants assessed the urgency to defecate using a daily diary response to the following question, "Have you felt or experienced a sense of urgency to pass stool today?". The change from the baseline value was calculated as the difference between the mean score (percentage of days) of the post-baseline interval (Weeks 9 to 12) and baseline. Baseline for the Extension Period was defined as non-missing assessment in Run-in period prior to the first dose of study drug. Core Phase: Baseline to Weeks 9-12; Extension Period: Baseline to Week 24
Secondary Change From Baseline in Sensation/Severity of Nausea Using 100 mm Visual Analog Scale (VAS) Sensation/severity of nausea was measured using a 100 mm VAS. Participants rated their perception of the sensation/severity of nausea experienced by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No vomiting and 100 = vomiting. The change from the baseline value was calculated as the difference between the mean score of the post-baseline interval (Weeks 9 to 12) and baseline. 0 indicates the best score, 100 indicates the worst score. Baseline for the Extension Period was defined as non-missing assessment in Run-in period prior to the first dose of study drug. Core Phase: Baseline to Weeks 9-12; Extension Period: Baseline to Week 24
Secondary Number of Participants With an Improvement in Global Assessment of Symptoms Associated With Carcinoid Syndrome Participants assessed their symptoms using a weekly subjective response to the following question, "In the past 7 days, have you had adequate relief of your carcinoid syndrome bowel complaints such as diarrhea, urgent need to have a bowel movement, abdominal pain, or discomfort?". The values for improvement in global assessment of symptoms associated with carcinoid syndrome in the Core Phase were averaged from Weeks 9 to 12. Core Phase: Weeks 9-12; Extension Period: Week 24
Secondary Change From Baseline in Daily Severity of Abdominal Pain or Discomfort Using 100 mm Visual Analog Scale (VAS) The severity of abdominal pain was measured using a 100 mm VAS. Participants rated their perception of the sensation/severity of abdominal pain or experienced by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No vomiting and 100 = vomiting. The change from the baseline value was calculated as the difference between the mean score of the post-baseline interval (Weeks 9 to 12) and baseline. 0 indicate the best score, 100 indicates the worst score. Baseline for the Extension Period was defined as non-missing assessment in Run-in period prior to the first dose of study drug. Core Phase: Baseline to Weeks 9-12; Extension Period: Baseline to Week 24
Secondary Change From Baseline in Daily Number of Cutaneous Flushing Episodes Participants recorded the number of daily cutaneous flushing episodes experienced in the daily diary. The change from baseline value was calculated as the difference between the mean numbers of cutaneous flushing episodes of the post-baseline interval (Weeks 9 to 12) and baseline. Baseline for the Extension Period was defined as non-missing assessment in Run-in period prior to the first dose of study drug. Core Phase: Baseline to Weeks 9-12; Extension Period: Baseline to Week 24
Secondary Number of Participants Achieving Clinically Meaningful Symptom Reduction in the Core Phase Clinically meaningful symptom reduction was defined as either: a) an average of < 4 bowel movements per day over 15 consecutive days, b) a 50% reduction from baseline in the number of bowel movements, c) a positive response to the question regarding adequate relief, or d) a 50% reduction from baseline in the number of daily flushing episodes. Baseline to Week 12
Secondary Change From Baseline in Urinary 5-Hydroxyindoleacetic Acid (HIAA) Levels Urinary 5-HIAA (u5-HIAA) is a standard test used in clinical practice to assess the neuroendocrine tumor (NET) activity and is collected as a 24-hour urine specimen. The change from baseline value for the Extension Period was calculated as the difference between mean change in 5-HIAA of the post-baseline interval (Weeks 20 to 21) and baseline. A negative change from baseline indicates improvement. Baseline for the Extension Period was defined as non-missing assessment in Run-in period prior to the first dose of study drug. Core Phase: Baseline to Week 12; Extension Period: Baseline to Weeks 20-21
See also
  Status Clinical Trial Phase
Recruiting NCT04993261 - An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors Early Phase 1
Not yet recruiting NCT04039516 - Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Phase 2
Completed NCT01234168 - A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Terminated NCT04073017 - Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency N/A
Recruiting NCT05756608 - Fibrosis in Chronic and Delayed Myocardial Infarction
Completed NCT00774930 - An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Phase 3
Withdrawn NCT04713202 - Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl Phase 2
Completed NCT00853047 - Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy Phase 2
Completed NCT02063659 - Telotristat Etiprate for Carcinoid Syndrome Therapy Phase 3
Withdrawn NCT04776876 - Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome Phase 2
Completed NCT03223428 - Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
Recruiting NCT03453489 - AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm Phase 2
Active, not recruiting NCT05361668 - Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Phase 2
Withdrawn NCT01172717 - Study of Panitumumab in the Treatment of Carcinoid Syndrome Phase 2
Terminated NCT00884715 - Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome Phase 1/Phase 2
Completed NCT01677910 - TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Phase 3
Completed NCT01430871 - Effects of Serotonin Excess on Bone in Carcinoid Syndrome N/A
Completed NCT02026063 - Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Phase 3
Terminated NCT01018953 - Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome Phase 2
Terminated NCT04140409 - Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation Phase 4